Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Fineline Cube Apr 28, 2026
Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Fineline Cube Apr 28, 2026
Company Drug

Shanghai Junshi Biosciences’ Tuoyi Shows Promise in Phase III Study for ES-SCLC

Fineline Cube May 8, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced encouraging results from the...

Policy / Regulatory

Tianjin, Shandong, and Hainan Provinces Announce VBP Backup Suppliers for Round 8

Fineline Cube May 8, 2023

Tianjin, Shandong, and Hainan provinces in China have released their lists of backup suppliers following...

Company Drug

Suzhou GenAssist’s GEN6050 Receives US FDA Pre-IND Acceptance for Duchenne Muscular Dystrophy Treatment

Fineline Cube May 8, 2023

China-based Suzhou GenAssist Therapeutic Co., Ltd has announced that the US Food and Drug Administration...

Company Deals

Sinopharm Partners with Fudan University to Establish National Innovation Platform

Fineline Cube May 8, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Fudan...

Company Drug

Reistone Biopharma’s Edralbrutinib Earns Orphan Drug Designation for NMOSD from US FDA

Fineline Cube May 8, 2023

Reistone Biopharma Co., Ltd, a company incubated by Hengrui Medicine with an investment of USD...

Company Deals

Lingyi Biotechnology Secures RMB 100 Million in Series A Funding for Gene Therapy Pipeline

Fineline Cube May 6, 2023

China-based gene therapy developer Lingyi Biotechnology Co., Ltd has reportedly raised close to RMB 100...

Company Drug

Henlius Biotech’s HLX26 and HaiSiZhuang Combo for NSCLC Gets NMPA Phase II Approval

Fineline Cube May 6, 2023

Shanghai Henlius Biotech (HKG: 2696) has announced that it has received approval from the National...

Company Deals

Shanghai Junshi Biosciences Inks Exclusive License Deal with Dr. Reddy’s Laboratories for Tuoyi

Fineline Cube May 6, 2023

Shanghai Junshi Biosciences Co., Ltd (SHA: 688180), a China-based biotechnology firm, has announced an exclusive...

Company Deals

Sinopharm Partners with Shenzhen to Boost High-End Medical Device and Pharmaceutical Innovation

Fineline Cube May 6, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Shenzhen...

Company Deals

XtalPi Inc. and China Pharmaceutical University Launch Joint AI Research Center in China

Fineline Cube May 6, 2023

Sino-US artificial intelligence (AI) firm XtalPi Inc. has joined forces with China Pharmaceutical University (CPU)...

Company Medical Device

Omega Medical Imaging’s Soteria.AI Receives FDA Approval for Interventional Cardiology

Fineline Cube May 6, 2023

US-based medical technology firm Omega Medical Imaging has received marketing approval from the US Food...

Policy / Regulatory

NMPA Extends Public Feedback Period for ‘Drug Standardization Management Measures’ in China

Fineline Cube May 6, 2023

The National Medical Products Administration (NMPA) in China has announced an extension to the public...

Company Deals

Hasten Biopharm Acquires Commercial Rights to Rocephin in China from Roche

Fineline Cube May 6, 2023

China-based Hasten Biopharmaceutical Co., Ltd has announced the acquisition of the commercial rights in China...

Company

Mindray Reports Strong YOY Growth in 2022 and Q1 2023 Financial Results

Fineline Cube May 6, 2023

China-based medical device firm Mindray (SHE: 300760) has released its financial reports for the year...

Policy / Regulatory

Anhui and Qinghai Provinces Update BMI Chronic Disease Drug Lists for Outpatient Reimbursement

Fineline Cube May 6, 2023

The healthcare security bureaus of Anhui and Qinghai provinces in China have separately released notifications...

Company Drug

Huadong Medicine’s Mefatinib Poised for Breakthrough Therapy Designation by CDE

Fineline Cube May 6, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Huadong Medicine Co., Ltd (SHE:...

Company Deals

VivaVision Biotech Secures Over RMB 100 Million in Series D2 Financing for Ophthalmology Pipeline Expansion

Fineline Cube May 5, 2023

China’s VivaVision Biotech Inc. has announced the successful completion of its Series D2 financing round,...

Company Drug

Yantai Dongcheng Pharma’s 177Lu-LNC1003 Cleared for US FDA Phase I Study

Fineline Cube May 5, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that it has received...

Company Drug

ABM Therapeutics’ ABM-168 Begins Phase I Dosing in the US for Advanced Solid Tumors

Fineline Cube May 5, 2023

Shanghai-based ABM Therapeutics, Inc. has announced the commencement of the first patient enrollment and dosing...

Company Deals

Kangrui Health Partners with West China Second University Hospital for Pediatric Care Innovation

Fineline Cube May 5, 2023

Kangrui Health, a leading data and intelligence application company based in Beijing, has entered into...

Posts pagination

1 … 521 522 523 … 658

Recent updates

  • Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform
  • Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise
  • AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise
  • GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
  • Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.